Malignant lymphoma of the testis.
Malignant lymphomas of the testis account for approximately 5 percent of testicular neoplasms, and they are the most common testicular malignancy between the ages of 60 and 80. Testicular lymphoma has a propensity to be associated with involvement of the skin, the central nervous system, Waldeyer's ring and adjacent structures, and the contralateral testicle. In general, essentially all patients with testicular lymphoma have been categorized as having "poor-risk" non-Hodgkin's lymphoma, with diffuse histiocytic lymphoma being the most common histologic subtype. All patients with testicular lymphoma should be treated with aggressive combination chemotherapy, with or without radiotherapy.
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001932:Brain Neoplasms / Q000517:prevention & control; D003131:Combined Modality Therapy; D003937:Diagnosis, Differential; D004407:Dysgerminoma / Q000175:diagnosis; D006801:Humans; D008223:Lymphoma / Q000175:diagnosis* / Q000628:therapy; D008297:Male; D009367:Neoplasm Staging; D009919:Orchiectomy; D011379:Prognosis; D013736:Testicular Neoplasms / Q000175:diagnosis* / Q000628:therapy; D013737:Testis / Q000473:pathology